GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » Operating Income

Medpace Holdings (Medpace Holdings) Operating Income : $355 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Operating Income?

Medpace Holdings's Operating Income for the three months ended in Mar. 2024 was $104 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $355 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Medpace Holdings's Operating Income for the three months ended in Mar. 2024 was $104 Mil. Medpace Holdings's Revenue for the three months ended in Mar. 2024 was $511 Mil. Therefore, Medpace Holdings's Operating Margin % for the quarter that ended in Mar. 2024 was 20.36%.

Good Sign:

Medpace Holdings Inc operating margin is expanding. Margin expansion is usually a good sign.

Medpace Holdings's 5-Year average Growth Rate for Operating Margin % was 5.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medpace Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was 21.58%. Medpace Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 159.25%.


Medpace Holdings Operating Income Historical Data

The historical data trend for Medpace Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Operating Income Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.26 167.04 198.62 278.70 336.83

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.20 78.39 84.91 87.32 104.07

Medpace Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $355 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings  (NAS:MEDP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medpace Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=416.276 * ( 1 - 9.04% )/( (1739.123 + 1770.026)/ 2 )
=378.6446496/1754.5745
=21.58 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1656.828 - 249.008 - ( 245.449 - max(0, 925.131 - 593.828+245.449))
=1739.123

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1795.789 - 237.506 - ( 407.01 - max(0, 956.645 - 744.902+407.01))
=1770.026

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medpace Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=416.276/( ( (265.39 + max(-599.22, 0)) + (257.403 + max(-627.234, 0)) )/ 2 )
=416.276/( ( 265.39 + 257.403 )/ 2 )
=416.276/261.3965
=159.25 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(275.932 + 0 + 49.979) - (249.008 + 559.86 + 116.263)
=-599.22

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(270.685 + 0 + 58.726) - (237.506 + 616.697 + 102.442)
=-627.234

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Medpace Holdings's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=104.069/511.044
=20.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Medpace Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (Medpace Holdings) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Executives
Susan E Burwig officer: Exec. VP, Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle director, 10 percent owner, officer: CEO 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc 10 percent owner 4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft director ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady officer: CFO & Treasurer MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald officer: General Counsel & Corp. Secy. C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar director 5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating director 5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr director
Brian T Carley director C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii director 5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger officer: CFO & COO, Lab Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King director 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP